Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer

Clin Adv Hematol Oncol. 2015 May;13(5):293-8.

Authors

Jing Li¹, Andrew J Armstrong¹

Affiliation

¹ Duke University, Durham, North Carolina.

PMID: 26352773

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Bone Neoplasms / drug therapy
Bone Neoplasms / radiotherapy
Bone Neoplasms / secondary
Brachytherapy / adverse effects
Clinical Decision-Making
Docetaxel
Humans
Male
Neoplasm Metastasis
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / pathology
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
Radium / adverse effects
Radium / therapeutic use*
Taxoids / adverse effects
Taxoids / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Taxoids
Docetaxel
Radium